VIPoma interventions: Difference between revisions

Jump to navigation Jump to search
(Created page with "__NOTOC__ {{VIPoma}} {{CMG}}{{AE}}{{Homa}} ==Overview== There are no recommended therapeutic interventions for the management of [disease name]. OR [Name of intervention] is...")
 
m (Bot: Removing from Primary care)
 
(2 intermediate revisions by one other user not shown)
Line 3: Line 3:
{{CMG}}{{AE}}{{Homa}}
{{CMG}}{{AE}}{{Homa}}
==Overview==
==Overview==
There are no recommended therapeutic interventions for the management of [disease name].
The mainstay of treatment for VIPoma is [[surgery]].  [[Hepatic artery]] [[embolization]] or transcatheter [[chemoembolization]] with [[doxorubicin]] or [[cisplatin]] is usually reserved for patients with [[liver]] [[metastases]]. Moreover, in [[patients]] with [[liver]] [[metastases]] less than 3 cm [[radiofrequency ablation]] and [[cryoablation]] can be used.


OR
==Indications==
 
[Name of intervention] is not the first-line treatment option for patients with [disease name]. [Name of intervention] is usually reserved for patients with either [indication 1], [indication 2], and [indication 3]
 
OR
 
The mainstay of treatment for [disease name] is medical therapy/surgery. [Name of intervention] is usually reserved for patients with either [indication 1], [indication 2], and/or [indication 3].
 
OR
 
The feasibility of [name of intervention] depends on the stage of [disease or malignancy] at the time of diagnosis.


OR
The mainstay of treatment for VIPoma is [[surgery]].  [[Hepatic artery]] [[embolization]] or transcatheter [[chemoembolization]] with [[doxorubicin]] or [[cisplatin]] is usually reserved for patients with [[liver]] [[metastases]]. Moreover, in [[patients]] with [[liver]] [[metastases]] less than 3 cm [[radiofrequency ablation]] and [[cryoablation]] can be used.<ref>{{Cite journal
| author = [[Julie King]], [[Richard Quinn]], [[Derek M. Glenn]], [[Julia Janssen]], [[Denise Tong]], [[Winston Liaw]] & [[David L. Morris]]
| title = Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases
| journal = [[Cancer]]
| volume = 113
| issue = 5
| pages = 921–929
| year = 2008
| month = September
| doi = 10.1002/cncr.23685
| pmid = 18618495
}}</ref><ref name="MougLeen2006">{{cite journal|last1=Moug|first1=Susan J.|last2=Leen|first2=Edward|last3=Horgan|first3=Paul G.|last4=Imrie|first4=Clement W.|title=Radiofrequency Ablation Has a Valuable Therapeutic Role in Metastatic VIPoma|journal=Pancreatology|volume=6|issue=1-2|year=2006|pages=155–159|issn=14243903|doi=10.1159/000090257}}</ref>


[Name of intervention] is the mainstay of treatment for [disease or malignancy].
==Indications==
The mainstay of treatment for TT is medical therapy.


==References==
==References==
Line 30: Line 26:
{{WH}}
{{WH}}
{{WS}}
{{WS}}
[[Category:Medicine]]
[[Category:Medicine]]
[[Category:Oncology]]
[[Category:Oncology]]
[[Category:Up-To-Date]]
[[Category:Up-To-Date]]
[[Category:Primary care]]
[[Category:Endocrinology]]
[[Category:Endocrinology]]
[[Category:Gastroenterology]]
[[Category:Gastroenterology]]

Latest revision as of 00:40, 30 July 2020

VIPoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Pathophysiology

Causes

Differentiating VIPoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Echocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Interventions

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

VIPoma interventions On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of VIPoma interventions

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on VIPoma interventions

CDC on VIPoma interventions

VIPoma interventions in the news

Blogs on VIPoma interventions

Directions to Hospitals Treating VIPoma

Risk calculators and risk factors for VIPoma interventions

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Homa Najafi, M.D.[2]

Overview

The mainstay of treatment for VIPoma is surgery. Hepatic artery embolization or transcatheter chemoembolization with doxorubicin or cisplatin is usually reserved for patients with liver metastases. Moreover, in patients with liver metastases less than 3 cm radiofrequency ablation and cryoablation can be used.

Indications

The mainstay of treatment for VIPoma is surgery. Hepatic artery embolization or transcatheter chemoembolization with doxorubicin or cisplatin is usually reserved for patients with liver metastases. Moreover, in patients with liver metastases less than 3 cm radiofrequency ablation and cryoablation can be used.[1][2]


References

  1. Julie King, Richard Quinn, Derek M. Glenn, Julia Janssen, Denise Tong, Winston Liaw & David L. Morris (2008). "Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases". Cancer. 113 (5): 921–929. doi:10.1002/cncr.23685. PMID 18618495. Unknown parameter |month= ignored (help)
  2. Moug, Susan J.; Leen, Edward; Horgan, Paul G.; Imrie, Clement W. (2006). "Radiofrequency Ablation Has a Valuable Therapeutic Role in Metastatic VIPoma". Pancreatology. 6 (1–2): 155–159. doi:10.1159/000090257. ISSN 1424-3903.

Template:WH Template:WS